瑞士Alentis生物技术公司筹集181.4M美元,用于推进新的癌症治疗临床试验。 Swiss biotech Alentis raises $181.4M to advance clinical trials for new cancer treatments.

瑞士生物技术公司Alentis治疗公司在OrbiMed、Jeito Capital和Novo控股公司领导的D系列筹资回合中筹集了1.814亿美元。 Swiss biotech company Alentis Therapeutics raised $181.4 million in a Series D funding round led by OrbiMed, Jeito Capital, and Novo Holdings. 这笔基金将支助两个新的ADC的临床试验,目标是“N1+肿瘤”,定于明年开始。 The funds will support clinical trials for two new ADCs targeting CLDN1+ tumors, set to begin next year. 这一投资标志着阿伦蒂斯在治疗固态肿瘤和纤维化疾病方面管道开发的巨大推动。 This investment marks a significant boost for Alentis' pipeline development in treating solid tumors and fibrotic diseases.